{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:07:41Z","timestamp":1791338861370,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12932"],"award-info":[{"award-number":["12932"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12932"],"award-info":[{"award-number":["12932"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12932"],"award-info":[{"award-number":["12932"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The introduction of immunotherapy and targeted therapy has drastically improved the life expectancy of patients with advanced cancer. Despite improved survival, obtaining long-term response can be highly distressing and comes with uncertainties that affect several life domains. The aim of this study is to gain a deeper understanding of long-term responders\u2019 lived experiences with obtaining long-term response to immunotherapy or targeted therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted an exploratory qualitative study using thematic data analysis. Semi-structured in-depth interviews were conducted with 17 patients with advanced melanoma or lung cancer who had a confirmed response to or long-term stable disease while on immunotherapy or targeted therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Long-term responders are living in a twilight zone, where they neither feel like a patient, nor feel healthy. This impacts their self-image, interactions with their social environment, and feelings of uncertainty. Due to their uncertain life perspective, long-term responders are going back and forth between hope and despair, while they are longing for their \u2018old\u2019 life, several barriers, such as protective behavior of the social environment, force them to adjust to a life with cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Long-term responders are facing many challenges, such as searching for a renewed identity, dealing with ongoing uncertainty, and having to adapt to a new normal. This emphasizes the importance of providing this new patient group with tailored information and support.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Implications for Cancer Survivors<\/jats:title>\n                <jats:p>Healthcare professionals can support patients by normalizing their feelings and providing space for varying emotions. Using patient-tailored scan frequencies could help temper fear of progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11764-022-01306-9","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T11:02:38Z","timestamp":1670670158000},"page":"750-760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Living in the twilight zone: a qualitative study on the experiences of patients with advanced cancer obtaining long-term response to immunotherapy or targeted therapy"],"prefix":"10.1007","volume":"18","author":[{"given":"Laura C.","family":"Zwanenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karijn P. M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie I.","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 J.","family":"Koldenhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"van Roozendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije L.","family":"van der Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie P. J.","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"1306_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40:127\u201337. https:\/\/doi.org\/10.1200\/JCO.21.02229.","journal-title":"J Clin Oncol"},{"key":"1306_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresec or metastatic melanoma. J Clin Oncol. 2015;33:1889\u201394. https:\/\/doi.org\/10.1200\/JCO.2014.56.2736.","journal-title":"J Clin Oncol"},{"key":"1306_CR3","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36:1668\u201374. https:\/\/doi.org\/10.1200\/JCO.2017.75.6270.","journal-title":"J Clin Oncol"},{"key":"1306_CR4","unstructured":"Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2015\/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018."},{"key":"1306_CR5","doi-asserted-by":"publisher","unstructured":"Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non\u2012Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(28):2518\u20132527. https:\/\/doi.org\/10.1200\/JCO.19.00934.","DOI":"10.1200\/JCO.19.00934"},{"key":"1306_CR6","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998. https:\/\/doi.org\/10.1001\/jama.2014.3741.","journal-title":"JAMA"},{"key":"1306_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1200\/OP.20.00183","volume":"16","author":"L Spoozak","year":"2020","unstructured":"Spoozak L, Wulff-Burchfield E, Brooks JV. Rallying cry from the place in between. JCO Oncol Pract. 2020;16:451\u20132. https:\/\/doi.org\/10.1200\/OP.20.00183.","journal-title":"JCO Oncol Pract"},{"key":"1306_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11764-019-00770-0","volume":"13","author":"J Lai-Kwon","year":"2019","unstructured":"Lai-Kwon J, Khoo C, Lo S, et al. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. J Cancer Surviv. 2019;13:503\u201311. https:\/\/doi.org\/10.1007\/s11764-019-00770-0.","journal-title":"J Cancer Surviv"},{"key":"1306_CR9","doi-asserted-by":"publisher","first-page":"E97","DOI":"10.1097\/NCC.0000000000000683","volume":"43","author":"D Milne","year":"2020","unstructured":"Milne D, Hyatt A, Billett A, et al. Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: \u201creal-world\u201d data. Cancer Nurs. 2020;43:E97\u2013104. https:\/\/doi.org\/10.1097\/NCC.0000000000000683.","journal-title":"Cancer Nurs"},{"key":"1306_CR10","doi-asserted-by":"publisher","first-page":"e032639","DOI":"10.1136\/bmjopen-2019-032639","volume":"10","author":"M Al-Achkar","year":"2020","unstructured":"Al-Achkar M, Marchand L, Thompson M, et al. Unmet needs and opportunities for improving care for patients with advanced lung cancer on targeted therapies: a qualitative study. BMJ Open. 2020;10:e032639. https:\/\/doi.org\/10.1136\/bmjopen-2019-032639.","journal-title":"BMJ Open"},{"key":"1306_CR11","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00520-018-4443-3","volume":"27","author":"D Levy","year":"2019","unstructured":"Levy D, Dhillon HM, Lomax A, et al. Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Support Care Cancer. 2019;27:1845\u201352. https:\/\/doi.org\/10.1007\/s00520-018-4443-3.","journal-title":"Support Care Cancer"},{"key":"1306_CR12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/08870446.2020.1867137","volume":"37","author":"GJ McGeechan","year":"2022","unstructured":"McGeechan GJ, Byrnes K, Campbell M, et al. A systematic review and qualitative synthesis of the experience of living with colorectal cancer as a chronic illness. Psychol Health. 2022;37:350\u201374. https:\/\/doi.org\/10.1080\/08870446.2020.1867137.","journal-title":"Psychol Health"},{"key":"1306_CR13","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2:e192535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535.","journal-title":"JAMA Netw Open"},{"key":"1306_CR14","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1056\/NEJMp1901103","volume":"380","author":"T Langbaum","year":"2019","unstructured":"Langbaum T, Smith TJ. Time to study metastatic-cancer survivorship. N Engl J Med. 2019;380:1300\u20132. https:\/\/doi.org\/10.1056\/NEJMp1901103.","journal-title":"N Engl J Med"},{"key":"1306_CR15","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00520-018-4524-3","volume":"27","author":"J Lacey","year":"2019","unstructured":"Lacey J, Lomax AJ, McNeil C, et al. A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. Support Care Cancer. 2019;27:1497\u2013507. https:\/\/doi.org\/10.1007\/s00520-018-4524-3.","journal-title":"Support Care Cancer"},{"key":"1306_CR16","volume-title":"Interpretative phenomenological analysis: theory, method and research","author":"JA Smith","year":"2009","unstructured":"Smith JA, Flower P, Larkin M. Interpretative phenomenological analysis: theory, method and research. London: Sage Publications; 2009."},{"key":"1306_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/bmj.320.7226.50","volume":"320","author":"N Mays","year":"2000","unstructured":"Mays N. Qualitative research in health care: assessing quality in qualitative research. BMJ. 2000;320:50\u20132. https:\/\/doi.org\/10.1136\/bmj.320.7226.50.","journal-title":"BMJ"},{"key":"1306_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-69909-7_3470-2","volume-title":"Thematic analysis: a practical guide","author":"V Braun","year":"2022","unstructured":"Braun V, Clarke V. Thematic analysis: a practical guide. London: SAGE Publications Ltd; 2022."},{"key":"1306_CR19","unstructured":"VERBI Software. MAXQDA 2020. Software. 2019. https:\/\/www.maxqda.com."},{"key":"1306_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11764-020-00853-3","volume":"14","author":"R Park","year":"2020","unstructured":"Park R, Shaw JW, Korn A, McAuliffe J. The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life. J Cancer Surviv. 2020;14:363\u201376. https:\/\/doi.org\/10.1007\/s11764-020-00853-3.","journal-title":"J Cancer Surviv"},{"key":"1306_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s11764-021-01024-8","volume":"15","author":"J Lai-Kwon","year":"2021","unstructured":"Lai-Kwon J, Heynemann S, Flore J, et al. Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. J Cancer Surviv. 2021;15:392\u20137. https:\/\/doi.org\/10.1007\/s11764-021-01024-8.","journal-title":"J Cancer Surviv"},{"key":"1306_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21670","author":"NCW Kamminga","year":"2022","unstructured":"Kamminga NCW, van der Veldt AAM, Joosen MCW, et al. Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma. Br J Dermatol. 2022. https:\/\/doi.org\/10.1111\/bjd.21670.","journal-title":"Br J Dermatol"},{"key":"1306_CR23","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.3390\/cancers14163889","volume":"14","author":"EEM Kolsteren","year":"2022","unstructured":"Kolsteren EEM, Deuning-Smit E, Chu AK, et al. Psychosocial aspects of living long term with advanced cancer and ongoing systemic treatment: a scoping review. Cancers (Basel). 2022;14:3889. https:\/\/doi.org\/10.3390\/cancers14163889.","journal-title":"Cancers (Basel)"},{"key":"1306_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/14779757.2013.767750","volume":"12","author":"R Elliott","year":"2013","unstructured":"Elliott R. Person-centered\/experiential psychotherapy for anxiety difficulties: theory, research and practice. Person-Centered Experiential Psychother. 2013;12:16\u201332. https:\/\/doi.org\/10.1080\/14779757.2013.767750.","journal-title":"Person-Centered Experiential Psychother"},{"key":"1306_CR25","doi-asserted-by":"publisher","unstructured":"Sharpe L, Michalowski M, Richmond B, et al. Fear of progression in chronic illnesses other than cancer: a systematic review and meta-analysis of a transdiagnostic construct. Health Psychol Rev 2022;1\u201320.https:\/\/doi.org\/10.1080\/17437199.2022.2039744","DOI":"10.1080\/17437199.2022.2039744"},{"issue":"2","key":"1306_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/resp.13965","volume":"25","author":"T Vaval\u00e0","year":"2020","unstructured":"Vaval\u00e0 T, Rigney M, Reale ML, et al. An examination of two dichotomies: women with lung cancer and living with lung cancer as a chronic disease. Respirology. 2020;25: Suppl 2:24\u201336. https:\/\/doi.org\/10.1111\/resp.13965.","journal-title":"Respirology"},{"key":"1306_CR27","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/pon.4290","volume":"26","author":"J Dunn","year":"2017","unstructured":"Dunn J, Watson M, Aitken JF, Hyde MK. Systematic review of psychosocial outcomes for patients with advanced melanoma. Psychooncology. 2017;26:1722\u201331.","journal-title":"Psychooncology"},{"key":"1306_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.genhosppsych.2019.04.001","volume":"60","author":"DC McFarland","year":"2019","unstructured":"McFarland DC. New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy. Gen Hosp Psychiatry. 2019;60:148\u201355. https:\/\/doi.org\/10.1016\/j.genhosppsych.2019.04.001.","journal-title":"Gen Hosp Psychiatry"},{"key":"1306_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cpr.2017.06.003","volume":"56","author":"L Curran","year":"2017","unstructured":"Curran L, Sharpe L, Butow P. Anxiety in the context of cancer: a systematic review and development of an integrated model. Clin Psychol Rev. 2017;56:40\u201354. https:\/\/doi.org\/10.1016\/j.cpr.2017.06.003.","journal-title":"Clin Psychol Rev"},{"key":"1306_CR30","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/pon.5468","volume":"29","author":"ML Lee","year":"2020","unstructured":"Lee ML, Schellekens MPJ. Bridging the distance: continuing psycho-oncological care via video-consults during the COVID -19 pandemic. Psychooncology. 2020;29:1421\u20133. https:\/\/doi.org\/10.1002\/pon.5468.","journal-title":"Psychooncology"},{"key":"1306_CR31","doi-asserted-by":"publisher","first-page":"e043215","DOI":"10.1136\/bmjopen-2020-043215","volume":"11","author":"KT Bui","year":"2021","unstructured":"Bui KT, Liang R, Kiely BE, et al. Scanxiety: a scoping review about scan-associated anxiety. BMJ Open. 2021;11:e043215. https:\/\/doi.org\/10.1136\/bmjopen-2020-043215.","journal-title":"BMJ Open"},{"key":"1306_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-022-01178-z","author":"JW Ankersmid","year":"2022","unstructured":"Ankersmid JW, Drossaert CHC, van Riet YEA, et al. Needs and preferences of breast cancer survivors regarding outcome-based shared decision-making about personalised post-treatment surveillance. J Cancer Surviv. 2022. https:\/\/doi.org\/10.1007\/s11764-022-01178-z.","journal-title":"J Cancer Surviv"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-022-01306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-022-01306-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-022-01306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T16:12:37Z","timestamp":1715271157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-022-01306-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1007\/s11764-022-01306-9","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethical Review Board of Tilburg School of Social and Behavioral Sciences (RP487) and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Recordings and transcriptions were stored on a secured server, to which only researchers of the Helen Dowling Institute have access. Anonymity of participants was ensured by linking each participant to an anonymized ID code. The file containing the link between personal information and the ID codes was encrypted and only accessible for MS, LZ, and AvR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no potential conflicts of interest with respect to the research, authorship and\/or publication of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}